Syneron Medical, Ltd. (ELOS)
Q1 2012 Earnings Call
May 9, 2012, 8:30 a.m. ET
Zack Kubow – The Ruth Group
Louis Scafuri – CEO
Asaf Alperovitz – CFO
Dr. Shimon Eckhouse – Chairman
Richard Newitter – Leerink Swann
Anthony Vendetti – Maxim Group
Good day, ladies and gentlemen, and welcome to the Syneron Medical Q1 2012 Results conference call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time. (Operator Instructions). As a reminder, today’s conference is being recorded.
I’d now like to turn the conference to your host, Mr. Zack Kubow of The Ruth Group. Please go ahead.
Thank you, operator. I’d like to welcome you to Syneron Medical’s first quarter 2012 conference call.
Statements on this call may be forward-looking within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 relating to the company’s future events or future performance, including statements with respect to Syneron’s expectations regarding, but not limited to, the financial forecast for 2012, the launch of new products and the maintenance of a leadership position in core and non-core markets.
Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the company’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in any forward-looking statements. These risks may include, but are not limited to the risk factors set forth under the heading Risk Factors in Syneron’s annual report on Form 20-F, filed with the SEC. These factors are updated from time to time through the filing of reports and registration statements with the SEC. These statements are only predictions and Syneron cannot guarantee that they will, in fact, occur.